June 26, 2014 / 10:36 AM / 3 years ago

Acorda's multiple sclerosis drug faces generic threat

1 Min Read

June 26 (Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.

Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.

Acorda said Actavis has submitted a marketing approval application with the U.S. Food and Drug Administration for a generic version of the drug.

Acorda said it intends to vigorously defend its intellectual property rights.

Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below